Step 1 of 5 · 2011–15

Digital Sequencing: error-corrected tumor DNA from a blood draw

Guardant's innovation was a way to read tumor DNA from a blood draw accurately enough to act on. Its Digital Sequencing attaches a barcode to each strand of every DNA fragment before sequencing, then compares the copies of each molecule so that errors made in the laboratory can be removed GDH-3. In the 2015 validation study, specificity was above 99.9999%, about one false positive in 1.56 million bases, while standard sequencing of the same sample produced 224 false positives; the test ran successfully on 99.8% of 1,000 consecutive clinical samples GDH-3. This mattered against Foundation Medicine, whose comprehensive genomic profiling test, FoundationOne, worked on tumor tissue. Its first blood test, FoundationACT, came only in May 2016 and was offered for patients whose tissue could not be profiled GDH-8. Guardant could make blood the main sample; Foundation treated it as the backup.

The founders came from sequencing technology. Helmy Eltoukhy had led advanced technology research at Illumina, the sequencing-machine maker, and AmirAli Talasaz had also been a senior director there; they met at the Stanford Genome Technology Center and founded Guardant in 2011 GDH-1 GDH-2. The result held up against tissue: in 165 matched blood and tissue samples from late-stage patients, the blood test's sensitivity was 85.0%, against 80.7% for tissue GDH-3. Guardant360, the commercial test built on the method, launched in 2014 GDH-1, and its accuracy is what let Guardant sell blood as the first test to order.

Rivals FoundationOne profiled tumor tissue; Foundation's first blood test, FoundationACT (May 2016), covered 62 genes and was positioned for patients unsuitable for a tissue biopsy GDH-8.

Novel Architecture

Step 2 of 5 · 2014–19

Blood-first profiling: results in under a week, no biopsy

Guardant sold Guardant360 as the first test to order, not the fallback. A blood draw removed the need for a new biopsy when tissue was scarce or risky to take, and could be repeated as the disease changed GH1. It was also fast: typical turnaround was under seven days in 2018 GDH-4, and Talasaz says competitors typically took about twice as long GDH-1. For a patient with advanced cancer, each week of waiting is a week without targeted treatment.

The NILE study made the case in lung cancer. Among 282 patients newly diagnosed with advanced non-small cell lung cancer (NSCLC), Guardant360 returned results in a median of 9 days against 15 for tissue, and three times as many patients received all the gene tests that guidelines recommend GDH-5. Where both results existed they agreed more than 90% of the time GDH-5. The gain came from patients whom tissue-first testing had left without a complete result: blood reached demand the standard did not serve. That demand could become routine ordering once payers and regulators accepted the test.

Rivals Foundation's FoundationOne Liquid (September 2018) cost $5,800 and returned results within two weeks; its chief commercial officer, Tom Civik, confined liquid biopsy to three cases (inaccessible tumors, patients too ill for a biopsy, too little tissue), and tissue stayed the standard choice for most patients GDH-9.

SpeedBlue Ocean Strategy

Step 4 of 5 · 2016–20

Test volume becomes a biopharma data business

Each clinical test also produced a genomic record, and Guardant sold that record to drug makers. Biopharma companies became a second customer group running alongside clinical testing: by 2018 Guardant worked with more than 40 of them, and its top five biopharma customers rose from 19.4% of total revenue in 2016 to 34.0% in the first half of 2018 GDH-4.

In June 2020 Guardant launched GuardantINFORM, which links more than 100,000 Guardant360 tests from five years of clinical use to de-identified medical and pharmacy claims GDH-7. Drug developers use it to find patients for targeted drugs, design trials and study drug resistance after approval GDH-7. The dataset grew with every test ordered in steps 2 and 3, so a laboratory with fewer tests had a smaller one to sell.

The same system, new tests

The laboratory, data and biopharma relationships then carried Guardant into new uses: Guardant Reveal, which looks for cancer remaining or returning after treatment, and Shield, approved by the FDA in July 2024 for colorectal-cancer screening GH1 GH2. Shared assets lowered the cost of entering each new use, but screening serves primary-care patients and needs its own evidence and payment, and Guardant still reported losses in 2025 GH1.

Rivals Roche, a drug maker, owned Foundation Medicine outright after a $2.4 billion acquisition in 2018 GDH-9, and that year analysts put Foundation's liquid-biopsy share at under a third of Guardant's GDH-12. Exact Sciences and Natera compete with Guardant in screening and residual-disease testing GH1.

Data ExhaustData LicensingScope economies